CRClaire A. Rushton

Claire A. Rushton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claire A. Rushton has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Umesh T Kadam

    Health Service Research Unit, Keele University, Staffordshire, UK

    4 shared publications
  • Anna Strömberg

    Department of Medical and Health Sciences, Linköping University, Sweden; Department of Cardiology, County Council of Östergötland, Sweden

    2 shared publications
  • Duwarakan Satchithananda

    The Heart Centre, Royal Stoke University Hospital, Stoke-on-Trent, UK

    2 shared publications
  • Mamas Andreas Mamas

    Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, United Kingdom; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, United Kingdom

    2 shared publications
  • Tiny Jaarsma

    Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden

    2 shared publications
  • Andrew Finney

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Preeclampsia and Future Cardiovascular Health

    by Pensée Wu, Randula Haththotuwa, Chun Shing Kwok, Aswin Babu, Rafail A. Kotronias, Claire Rushton, Azfar Zaman, Anthony A. Fryer, Umesh Kadam, Carolyn A. Chew-Graham, et al.

    Background—Preeclampsia is a pregnancy-specific disorder resulting in hypertension and multiorgan dysfunction. There is growing evidence that these effects persist after pregnancy. We aimed to systematically evaluate and quantify the evidence on the relationship between preeclampsia and the future risk of cardiovascular diseases. Methods and Results—We studied the future risk of heart failure, coronary heart disease, composite cardiovascular disease, death because of coronary heart or cardiovascular disease, stroke, and stroke death after preeclampsia. A systematic search of MEDLINE and EMBASE was performed to identify relevant studies. We used random-effects meta-analysis to determine the risk. Twenty-two studies were identified with >6.4 million women including >258 000 women with preeclampsia. Meta-analysis of studies that adjusted for potential confounders demonstrated that preeclampsia was independently associated with an increased risk of future heart failure (risk ratio [RR], 4.19; 95% confidence interval [CI], 2.09–8.38), coronary heart disease (RR, 2.50; 95% CI, 1.43–4.37), cardiovascular disease death (RR, 2.21; 95% CI, 1.83–2.66), and stroke (RR, 1.81; 95% CI, 1.29–2.55). Sensitivity analyses showed that preeclampsia continued to be associated with an increased risk of future coronary heart disease, heart failure, and stroke after adjusting for age (RR, 3.89; 95% CI, 1.83–8.26), body mass index (RR, 3.16; 95% CI, 1.41–7.07), and diabetes mellitus (RR, 4.19; 95% CI, 2.09–8.38). Conclusions—Preeclampsia is associated with a 4-fold increase in future incident heart failure and a 2-fold increased risk in coronary heart disease, stroke, and death because of coronary heart or cardiovascular disease. Our study highlights the importance of lifelong monitoring of cardiovascular risk factors in women with a history of preeclampsia.


  • Ultrafiltration for acute decompensated cardiac failure: A systematic review and meta-analysis

    by Chun Shing Kwok, Chun Wai Wong, Claire A. Rushton, Fozia Ahmed, Colin Cunnington, Simon J. Davies, Ashish Patwala, Mamas A. Mamas, Duwarakan Satchithananda


  • Open Access

    Heart Failure Association of the European Society of Cardiology Heart Failure Nurse Curriculum

    by Jillian P. Riley, Felicity Astin, Marisa G. Crespo-Leiro, Christi M. Deaton, Jens Kienhorst, Ekaterini Lambrinou, Theresa A. McDonagh, Claire A. Rushton, Anna Stromberg, Gerasimos Filippatos, et al.

    Recent advances in care and management of heart failure have improved outcome, largely as a result of the developing evidence basis for medications, implantable devices and the organization of heart failure follow-up. Such developments have also increased the complexity of delivering and coordinating care. This has led to a change to the way in which heart failure services are organized and to the traditional role of the heart failure nurse. Nurses in many countries now provide a range of services that include providing care for patients with acute and with chronic heart failure, working in and across different sectors of care (inpatient, outpatient, community care, the home and remotely), organising care services around the face-to-face and the remote collection of patient data, and liaising with a wide variety of health-care providers and professionals. To support such advances the nurse requires a skill set that goes beyond that of their initial education and training. The range of nurses’ roles across Europe is varied. So too is the nature of their educational preparation. This heart failure nurse curriculum aims to provide a framework for use in countries of the European Society of Cardiology. Its modular approach enables the key knowledge, skills, and behaviours for the nurse working in different care settings to be outlined and so facilitate nursing staff to play a fuller role within the heart failure team.


  • The challenge of multimorbidity in nurse education: An international perspective

    by Claire A. Rushton, Julie Green, Tiny Jaarsma, Pauline Walsh, Anna Strömberg, Umesh T. Kadam


  • Heart failure and chronic obstructive pulmonary disease multimorbidity at hospital discharge transition: a study of patient and carer experience

    by Lucy Doos, Eleanor Bradley, Claire A Rushton, Duwarakan Satchithananda, Simon J Davies, Umesh T Kadam

    Background: Care for patients with multimorbidity represents a major challenge not only for patients and carers but to health‐care systems. Hospital discharge transition is a critical point at which challenges for multimorbidity may amplify.Objectives: The main objective of the study was to explore the experiences of heart failure (HF) and chronic obstructive pulmonary disease (COPD) multimorbid patients and their carers on hospital discharge. Secondary objectives included identification of gaps in the health care of multimorbidity and optimal solutions from patients and carers' perspectives.Design: Mixed methods were applied to collect data using patient self‐completion questionnaire from an adapted version of the American Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey and in‐depth interviews.Setting: Participants were recruited from two cardiology and respiratory wards at a large regional hospital in England, and all had a multimorbidity diagnosis of COPD and HF.Results and conclusions: Findings revealed that patients experienced difficulties in their communication with health‐care professionals and there were specific challenges with information about medication. Qualitative descriptions revealed that experiences fell into two main categories: (i) information transfer to patients with multimorbidity in terms of issues with medication and clarity of information on diagnosis and (ii) communication and continuity of care after discharge. Respondents highlighted gaps in the management of patients with multimorbidity of HF and COPD at the critical time of care transition. They suggested the need for a comprehensive, coordinated and integrated approach to incorporate patients, carers and staff preferences for treatment on discharge from hospital.


  • Open Access

    Multidrug and optimal heart failure therapy prescribing in older general practice populations: a clinical data linkage study

    by Claire A Rushton, Anna Strömberg, Tiny Jaarsma, Umesh T Kadam

    Objective To investigate multidrug therapy in the cardiovascular disease (CVD) population and whether it was associated with suboptimal drug prescribing in heart failure (HF). Design A population-based cross-sectional clinical data linkage study. Setting The clinical database populations were registered with three general practices in North Staffordshire that are part of a research network. Participants 3155 patients aged 50 years and over were selected on the basis of a CVD-related prescription and a CVD consultation code applied to their electronic medical record in a 2-year time period. All available diagnostic data were linked to all drugs prescribed data during this time period. Two study groups were: (1) HF and (2) non-HF CVD (reference group). Exposure A standard drug formulary system was used to define four multidrug count categories based on the number of different British National Formulary drug chapters prescribed at the same time. Primary and secondary outcome measures Optimal HF therapy was defined as the prescribing of ACE inhibitor (ACEi) or a combination of ACEi and β-blocker in the 2-year time window. An additional three specific CVD drug categories that are indicated in HF were also measured. Results The HF group, compared with the reference group, had higher non-CVD multidrug therapy (26% with 7 or more counts compared with 14% in the non-HF CVD reference group). For the first-choice optimal drug treatment for HF with ACEi (64%) or ACEi and β-blocker combined therapy (23%), the multidrug-adjusted associations between the HF group and the reference group were OR 3.89; 95% CI 2.8 to 5.5 and 1.99; 1.4 to 2.9, respectively. These estimates were not influenced by adjustment for sociodemographic factors and multidrug counts. Conclusions Multidrug therapy prescribing is much higher in the HF group than in a comparable CVD group but did not influence optimal drug prescribing.


  • Open Access

    Comorbidity Cohort (2C) study: Cardiovascular disease severity and comorbid osteoarthritis in primary care

    by James A Prior, Claire A Rushton, Kelvin P Jordan, Umesh T Kadam

    Two of the commonest chronic diseases experienced by older people in the general population are cardiovascular diseases and osteoarthritis. These conditions also commonly co-occur, which is only partly explained by age. Yet, there have been few studies investigating specific a priori hypotheses in testing the comorbid interaction between two chronic diseases and related health and healthcare outcomes. It is also unknown whether the stage or severity of the chronic disease influences the comorbidity impact. The overall plan is to investigate the interaction between cardiovascular severity groups (hypertension, ischaemic heart disease and heart failure) and osteoarthritis comorbidity, and their longitudinal impact on health and healthcare outcomes relative to either condition alone.